Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016

BACKGROUND: Preclinical studies have demonstrated that docetaxel and bevacizumab may act synergistically by decreasing endothelial cell proliferation and preventing circulating endothelial progenitor mobilization. The objective of this study was to assess the efficacy and safety of a combination the...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:BMC Cancer
Main Authors: Ikeda, Satoshi, Kato, Terufumi, Ogura, Takashi, Sekine, Akimasa, Oda, Tsuneyuki, Masuda, Noriyuki, Igawa, Satoshi, Katono, Ken, Otani, Sakiko, Yamada, Kouzo, Saito, Haruhiro, Kondo, Tetsuro, Hosomi, Yukio, Nakahara, Yoshiro, Nishikawa, Masanori, Utumi, Keiko, Misumi, Yuki, Yamanaka, Takeharu, Sakamaki, Kentaro, Okamoto, Hiroaki
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2018
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5833040/
https://ncbi.nlm.nih.gov/pubmed/29499653
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4150-y
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki